G. Ngarmchamnanrith

发表

Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial.

Myung Ah Lee, J. Krauss, V. Heinemann, 2021, The Lancet. Oncology.

Impact of QRS Duration in Heart Failure with Preserved Ejection Fraction

P. Nijjar, Kairav P. Vakil, S. Pomerantz, 2014 .

Sotorasib for Lung Cancers with KRAS p.G12C Mutation.

R. Govindan, S. Ramalingam, V. Velcheti, 2021, The New England journal of medicine.

Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor–related protein agonist AMG 228 in patients with advanced solid tumors

E. Rasmussen, P. LoRusso, B. Tran, 2018, Journal of Immunotherapy for Cancer.

Phase I study of AMG 510, a novel molecule targeting KRAS G12C mutant solid tumours

J. Desai, R. Govindan, J. Krauss, 2019, Annals of Oncology.

of 208, an oral MET inhibitor, in adult patients with advanced solid tumors.

R. Loberg, F. Janku, D. Hong, 2015 .

Clinical activity of AMG 337, an oral MET kinase inhibitor, in adult patients (pts) with MET-amplified gastroesophageal junction (GEJ), gastric (G), or esophageal (E) cancer.

P. LoRusso, T. Bekaii-Saab, E. Chan, 2015 .

OA02.02 Phase 1 Study of Safety, Tolerability, PK and Efficacy of AMG 510, a Novel KRASG12C Inhibitor, Evaluated in NSCLC

J. Desai, R. Govindan, J. Krauss, 2019, Journal of Thoracic Oncology.

Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma

E. Rasmussen, N. Raje, A. Avilion, 2020, Leukemia.

Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors

R. Loberg, P. LoRusso, T. Bekaii-Saab, 2018, Clinical Cancer Research.

First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma

E. Rasmussen, J. Soria, A. Lockhart, 2019, Cancer Chemotherapy and Pharmacology.

A retrospective observational study of the natural history of advanced non-small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease.

S. Aggarwal, J. Gray, A. Spira, 2021, Lung cancer.

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.

J. Desai, R. Govindan, J. Krauss, 2020, The New England journal of medicine.

First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors

A. Tolcher, E. Rasmussen, K. Papadopoulos, 2017, Clinical Cancer Research.

First-inHuman Study of AMG 820 , a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody , in Patients with Advanced Solid Tumors

A. Tolcher, E. Rasmussen, K. Papadopoulos, 2017 .

Registrational phase 2 trial of sotorasib in KRAS p. G12C mutant NSCLC: first disclosure of the CodeBreaK 100 primary analysis

V. Velcheti, H. Borghaei, M. Schuler, 2021, Pneumologie.

CodeBreak 100: Activity of AMG 510, a novel small molecule inhibitor of KRASG12C, in patients with advanced colorectal cancer.

J. Desai, J. Krauss, Keunchil Park, 2020 .

Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer.

T. Burns, D. Juric, M. Schuler, 2022, The New England journal of medicine.

First-in-human study of AMG 337, a highly selective oral inhibitor of MET, in adult patients (pts) with advanced solid tumors.

R. Loberg, P. LoRusso, E. Kwak, 2014 .

CodeBreak 100: Phase I study of AMG 510, a novel KRASG12C inhibitor, in patients (pts) with advanced solid tumors other than non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).

J. Krauss, T. Burns, D. Hong, 2020, Journal of Clinical Oncology.

Overall survival and exploratory subgroup analyses from the phase 2 CodeBreaK 100 trial evaluating sotorasib in pretreated KRAS p.G12C mutated non-small cell lung cancer.

R. Govindan, G. Shapiro, V. Velcheti, 2021 .

Clinical Implications and Translation of an Off-Target Pharmacology Profiling Hit: Adenosine Uptake Inhibition In Vitro

I. Dimery, J. Werner, H. Vargas, 2019, Translational oncology.

A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors

R. Loberg, R. Kurzrock, F. Janku, 2015, Oncotarget.

Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS G12C mutation: a randomised, open-label, phase 3 trial

C. Dooms, Melissa L. Johnson, S. Novello, 2023, The Lancet.

Dose escalation results from a first-in-human, phase 1 study of the glucocorticoid-induced TNF receptor-related protein (GITR) agonist AMG 228 in patients (Pts) with advanced solid tumors.

E. Rasmussen, P. LoRusso, B. Tran, 2017 .